# A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

> **NCT06860269** · PHASE2,PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1200 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Randomization + Blinatumomab + chemotherapy
- **OTHER:** Randomization + Standard frontline T-ALL chemotherapy backbone
- **DRUG:** Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone
- **DRUG:** Randomization + Blinatumomab + Ponatinib + chemotherapy
- **OTHER:** Randomization 1 + Allo HSCT
- **OTHER:** Randomization 2 + Allo HSCT

## Key facts

- **NCT ID:** NCT06860269
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2035-03-15
- **Final completion:** 2035-03-15
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860269, "A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06860269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*